Cargando…

Anti-stress neuropharmacological mechanisms and targets for addiction treatment: A translational framework

Stress-related substance use is a major challenge for treating substance use disorders. This selective review focuses on emerging pharmacotherapies with potential for reducing stress-potentiated seeking and consumption of nicotine, alcohol, marijuana, cocaine, and opioids (i.e., key phenotypes for t...

Descripción completa

Detalles Bibliográficos
Autor principal: Greenwald, Mark K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6138948/
https://www.ncbi.nlm.nih.gov/pubmed/30238023
http://dx.doi.org/10.1016/j.ynstr.2018.08.003
_version_ 1783355433838182400
author Greenwald, Mark K.
author_facet Greenwald, Mark K.
author_sort Greenwald, Mark K.
collection PubMed
description Stress-related substance use is a major challenge for treating substance use disorders. This selective review focuses on emerging pharmacotherapies with potential for reducing stress-potentiated seeking and consumption of nicotine, alcohol, marijuana, cocaine, and opioids (i.e., key phenotypes for the most commonly abused substances). I evaluate neuropharmacological mechanisms in experimental models of drug-maintenance and relapse, which translate more readily to individuals presenting for treatment (who have initiated and progressed). An affective/motivational systems model (three dimensions: valence, arousal, control) is mapped onto a systems biology of addiction approach for addressing this problem. Based on quality of evidence to date, promising first-tier neurochemical receptor targets include: noradrenergic (α1 and β antagonist, α2 agonist), kappa-opioid antagonist, nociceptin antagonist, orexin-1 antagonist, and endocannabinoid modulation (e.g., cannabidiol, FAAH inhibition); second-tier candidates may include corticotropin releasing factor-1 antagonists, serotonergic agents (e.g., 5-HT reuptake inhibitors, 5-HT3 antagonists), glutamatergic agents (e.g., mGluR2/3 agonist/positive allosteric modulator, mGluR5 antagonist/negative allosteric modulator), GABA-promoters (e.g., pregabalin, tiagabine), vasopressin 1b antagonist, NK-1 antagonist, and PPAR-γ agonist (e.g., pioglitazone). To address affective/motivational mechanisms of stress-related substance use, it may be advisable to combine agents with actions at complementary targets for greater efficacy but systematic studies are lacking except for interactions with the noradrenergic system. I note clinically-relevant factors that could mediate/moderate the efficacy of anti-stress therapeutics and identify research gaps that should be pursued. Finally, progress in developing anti-stress medications will depend on use of reliable CNS biomarkers to validate exposure-response relationships.
format Online
Article
Text
id pubmed-6138948
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-61389482018-09-20 Anti-stress neuropharmacological mechanisms and targets for addiction treatment: A translational framework Greenwald, Mark K. Neurobiol Stress Article Stress-related substance use is a major challenge for treating substance use disorders. This selective review focuses on emerging pharmacotherapies with potential for reducing stress-potentiated seeking and consumption of nicotine, alcohol, marijuana, cocaine, and opioids (i.e., key phenotypes for the most commonly abused substances). I evaluate neuropharmacological mechanisms in experimental models of drug-maintenance and relapse, which translate more readily to individuals presenting for treatment (who have initiated and progressed). An affective/motivational systems model (three dimensions: valence, arousal, control) is mapped onto a systems biology of addiction approach for addressing this problem. Based on quality of evidence to date, promising first-tier neurochemical receptor targets include: noradrenergic (α1 and β antagonist, α2 agonist), kappa-opioid antagonist, nociceptin antagonist, orexin-1 antagonist, and endocannabinoid modulation (e.g., cannabidiol, FAAH inhibition); second-tier candidates may include corticotropin releasing factor-1 antagonists, serotonergic agents (e.g., 5-HT reuptake inhibitors, 5-HT3 antagonists), glutamatergic agents (e.g., mGluR2/3 agonist/positive allosteric modulator, mGluR5 antagonist/negative allosteric modulator), GABA-promoters (e.g., pregabalin, tiagabine), vasopressin 1b antagonist, NK-1 antagonist, and PPAR-γ agonist (e.g., pioglitazone). To address affective/motivational mechanisms of stress-related substance use, it may be advisable to combine agents with actions at complementary targets for greater efficacy but systematic studies are lacking except for interactions with the noradrenergic system. I note clinically-relevant factors that could mediate/moderate the efficacy of anti-stress therapeutics and identify research gaps that should be pursued. Finally, progress in developing anti-stress medications will depend on use of reliable CNS biomarkers to validate exposure-response relationships. Elsevier 2018-08-11 /pmc/articles/PMC6138948/ /pubmed/30238023 http://dx.doi.org/10.1016/j.ynstr.2018.08.003 Text en © 2018 The Author http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Greenwald, Mark K.
Anti-stress neuropharmacological mechanisms and targets for addiction treatment: A translational framework
title Anti-stress neuropharmacological mechanisms and targets for addiction treatment: A translational framework
title_full Anti-stress neuropharmacological mechanisms and targets for addiction treatment: A translational framework
title_fullStr Anti-stress neuropharmacological mechanisms and targets for addiction treatment: A translational framework
title_full_unstemmed Anti-stress neuropharmacological mechanisms and targets for addiction treatment: A translational framework
title_short Anti-stress neuropharmacological mechanisms and targets for addiction treatment: A translational framework
title_sort anti-stress neuropharmacological mechanisms and targets for addiction treatment: a translational framework
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6138948/
https://www.ncbi.nlm.nih.gov/pubmed/30238023
http://dx.doi.org/10.1016/j.ynstr.2018.08.003
work_keys_str_mv AT greenwaldmarkk antistressneuropharmacologicalmechanismsandtargetsforaddictiontreatmentatranslationalframework